Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count - PubMed (original) (raw)
. 1998 Jan 7;279(1):35-40.
doi: 10.1001/jama.279.1.35.
Affiliations
- PMID: 9424041
- DOI: 10.1001/jama.279.1.35
Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count
D Vlahov et al. JAMA. 1998.
Abstract
Context: Plasma human immunodeficiency virus type 1 (HIV-1) viral load and CD4+ cell count are used to predict prognosis of persons infected with HIV. However, whether combining these markers improves prognostic accuracy and whether they predict prognosis for injection drug users (IDUs) and nonwhite persons infected with HIV has not been extensively investigated.
Objective: To evaluate plasma viral load and CD4+ cell count as prognostic indicators for the acquired immunodeficiency syndrome (AIDS) and infectious disease deaths.
Design: Cohort study initiated in 1988 and 1989 with follow-up for up to 7.9 years.
Participants: Injection drug users infected with HIV recruited from the community in Baltimore, Md.
Main outcome measures: Plasma HIV-1 RNA and CD4+ cell count measured at baseline compared with time to first clinical AIDS diagnosis and death due to an infectious disease.
Results: Of 522 subjects, 96% were African American, 80% were male, 96% injected drugs within the past 6 months, and the median age was 33 years. A total of 146 cases of AIDS and 119 infectious disease deaths were seen during a median follow-up period of 6.4 years. Time-fixed baseline levels of viral load and CD4+ cell count were independent predictors of progression to AIDS and infectious disease deaths, but in proportional hazards models, viral load had better predictive value than CD4+ cell count. Kaplan-Meier analysis of time to AIDS and to infectious disease deaths by viral load (<500, 500-9999, 10000-29 999, > or =30000 copies/mL) at 3 levels of CD4+ cell count (<0.20, 0.20-0.49, and > or =0.50x10(9)/L [<200,200-499, and > or =500/microL]) was reduced to a 5-stage classification scheme using a backward stepwise regression procedure. The 5-year cumulative probabilities for AIDS and infectious disease deaths ranged from 0% and 0%, respectively, for group I (viral load, <500 copies/mL; CD4+ cell count, 0.50x10(9)/L) to 81.2% and 76.1% respectively, for group V (viral load, > or =10000 copies/mL; CD4+ cell count, 0.20x10(9)/L).
Conclusions: In this study, plasma HIV-1 viral load independently and in combination with CD4+ cell count measurements provided powerful prognostic information for progression to AIDS and death caused by infectious disease in a population of predominantly African American IDUs. Combining categories of both markers provided a simple method for prognostically staging HIV disease.
Similar articles
- Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.
Mellors JW, Muñoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R, Phair JP, Rinaldo CR Jr. Mellors JW, et al. Ann Intern Med. 1997 Jun 15;126(12):946-54. doi: 10.7326/0003-4819-126-12-199706150-00003. Ann Intern Med. 1997. PMID: 9182471 - Psychological distress and progression to AIDS in a cohort of injection drug users.
Golub ET, Astemborski JA, Hoover DR, Anthony JC, Vlahov D, Strathdee SA. Golub ET, et al. J Acquir Immune Defic Syndr. 2003 Apr 1;32(4):429-34. doi: 10.1097/00126334-200304010-00013. J Acquir Immune Defic Syndr. 2003. PMID: 12640202 - Sex differences in HIV-1 viral load and progression to AIDS.
Farzadegan H, Hoover DR, Astemborski J, Lyles CM, Margolick JB, Markham RB, Quinn TC, Vlahov D. Farzadegan H, et al. Lancet. 1998 Nov 7;352(9139):1510-4. doi: 10.1016/S0140-6736(98)02372-1. Lancet. 1998. PMID: 9820299 - Introduction and immunopathogenesis of acquired immune deficiency syndrome.
Sudharshan S, Biswas J. Sudharshan S, et al. Indian J Ophthalmol. 2008 Sep-Oct;56(5):357-62. doi: 10.4103/0301-4738.42411. Indian J Ophthalmol. 2008. PMID: 18711263 Free PMC article. Review. - AIDS cases in Ottawa: A review of simultaneous HIV and AIDS diagnoses.
Orser L, O'Byrne P, Holmes D. Orser L, et al. Public Health Nurs. 2022 Sep;39(5):909-916. doi: 10.1111/phn.13065. Epub 2022 Mar 19. Public Health Nurs. 2022. PMID: 35305282 Free PMC article. Review.
Cited by
- HLA-mismatched allogeneic adoptive immune therapy in patients with severely immunosuppressed AIDS: a multicenter, open-label, controlled, phase 2a study.
Yang T, Xie Z, Xu Z, Tu B, Lu H, Huang H, Huang L, Zhang C, Gao L, Jin L, Ma P, Zou J, Liu L, Zhen C, Zhou C, Meng S, Li YY, Song JW, Yang S, Ai HS, Jiao Y, Shi M, Xu R, Wang FS. Yang T, et al. Emerg Microbes Infect. 2024 Dec;13(1):2364744. doi: 10.1080/22221751.2024.2364744. Epub 2024 Jun 27. Emerg Microbes Infect. 2024. PMID: 38935839 Free PMC article. Clinical Trial. - HIV-1 infection of genetically engineered iPSC-derived central nervous system-engrafted microglia in a humanized mouse model.
Min AK, Javidfar B, Missall R, Doanman D, Durens M, Graziani M, Mordelt A, Marro SG, de Witte L, Chen BK, Swartz TH, Akbarian S. Min AK, et al. J Virol. 2023 Dec 21;97(12):e0159523. doi: 10.1128/jvi.01595-23. Epub 2023 Nov 30. J Virol. 2023. PMID: 38032195 Free PMC article. - Unsuppressed viral load after intensive adherence counselling in rural eastern Uganda; a case of Kamuli district, Uganda.
Ndikabona G, Alege JB, Kirirabwa NS, Kimuli D. Ndikabona G, et al. BMC Public Health. 2021 Dec 18;21(1):2294. doi: 10.1186/s12889-021-12366-4. BMC Public Health. 2021. PMID: 34922502 Free PMC article. - rs1445776009 variants in the human ALB gene: Association with serum albumin and clinical outcomes in HIV-infected Kenyan injection substance users.
Barasa E, Shaviya N, Budambula V, Were T. Barasa E, et al. Int J Health Sci (Qassim). 2021 May-Jun;15(3):3-11. Int J Health Sci (Qassim). 2021. PMID: 34234630 Free PMC article. - Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia.
Belay YB, Ali EE, Chung KY, Gebretekle GB, Sander B. Belay YB, et al. Pharmacoecon Open. 2021 Dec;5(4):655-664. doi: 10.1007/s41669-021-00275-6. Epub 2021 Jun 16. Pharmacoecon Open. 2021. PMID: 34133017 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous